Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults

• Status: Completed
• Trial end date: 2013-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to examine the effect of memantine and buprenorphine on opioid abusing behavior, to determine the effect of memantine and buprenorphine on early relapse and to evaluate the tolerability of memantine co-administrated with buprenorphine. The study seeks to determine if combined treatment of memantine and buprenorphine may provide shorter-term treatment for opioid dependence.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Massachusetts, Worcester
• Collaborator: National Institute on Drug Abuse (NIDA)
• Treatments: Buprenorphine; Memantine

Criteria

Inclusion Criteria:

• Men and women between 18-25 years old

• Opioid dependence as evidenced by signs of opiate withdrawal, self-reported history of opioid dependence for a consecutive 12 month period and positive urine for opioids

Exclusion Criteria:

• Current diagnosis of other drug or alcohol dependence (other than opiates, cannabis or tobacco)

• Serious medical illness (e.g. major cardiovascular, renal, endocrine, hepatic disorder)

• Current serious psychiatric illness or history of psychosis, schizophrenia, bipolar type I disorder and participants with suicidal or homicidal thoughts

• Women who are pregnant, nursing or refuse to use a reliable form of birth control or refuse monthly pregnancy testing

• Screening liver function tests (SGOT or SGPT) greater than 3 times normal